Literature DB >> 23694773

Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.

Thomas G von Lueder1, S Jeson Sangaralingham, Bing H Wang, Andrew R Kompa, Dan Atar, John C Burnett, Henry Krum.   

Abstract

Entities:  

Keywords:  BNP; angiotensin II; heart failure; natriuretic peptides; neprilysin; renin-angiotensin system

Mesh：

Substances：

Year:  2013        PMID： 23694773      PMCID： PMC3981104          DOI： 10.1161/CIRCHEARTFAILURE.112.000289

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  110 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Effect of nesiritide in patients with acute decompensated heart failure.

Authors:  C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

3.  Physiological relevance of hydrolysis of atrial natriuretic peptide by endothelin-converting enzyme-1.

Authors:  Kazuhiko Nakayama; Noriaki Emoto; Yoko Suzuki; Nicolas Vignon-Zellweger; Keiko Yagi; Ken-ichi Hirata
Journal:  Kobe J Med Sci       Date:  2012-06-21

4.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Authors:  Henry Krum; Barry Massie; William T Abraham; Kenneth Dickstein; Lars Kober; John J V McMurray; Ashkay Desai; Claudio Gimpelewicz; Albert Kandra; Bernard Reimund; Henning Rattunde; Juergen Armbrecht
Journal:  Eur J Heart Fail       Date:  2011-01       Impact factor: 15.534

5.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

Authors:  J L Rouleau; M A Pfeffer; D J Stewart; D Isaac; F Sestier; E K Kerut; C B Porter; G Proulx; C Qian; A J Block
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

6.  Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Authors:  Jessie Gu; Adele Noe; Priya Chandra; Suliman Al-Fayoumi; Monica Ligueros-Saylan; Ramesh Sarangapani; Suzanne Maahs; Gary Ksander; Dean F Rigel; Arco Y Jeng; Tsu-Han Lin; Weiyi Zheng; William P Dole
Journal:  J Clin Pharmacol       Date:  2009-11-23       Impact factor: 3.126

7.  Mechanisms of elevated plasma endothelin-1 in CHF: congestion increases pulmonary synthesis and secretion of endothelin-1.

Authors:  Thomas G von Lueder; Harald Kjekshus; Thor Edvardsen; Erik ØIe; Stig Urheim; Leif Erik Vinge; Muhammed Shakil Ahmed; Otto A Smiseth; Håvard Attramadal
Journal:  Cardiovasc Res       Date:  2004-07-01       Impact factor: 10.787

8.  Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma.

Authors:  A J Stingo; A L Clavell; D M Heublein; C M Wei; M R Pittelkow; J C Burnett
Journal:  Am J Physiol       Date:  1992-10

9.  Angiotensin II receptors subtypes mediate diverse gene expression profile in adult hypertrophic cardiomyocytes.

Authors:  Juan Zhou; Xin Xu; Jin-Jun Liu; Yuan-Xi Lin; Guang-Dao Gao
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-11       Impact factor: 2.557

Review 10.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951
View more
  46 in total

Review 1.  Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.

Authors:  Fayez El Shear
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

2.  Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.

Authors:  Lodi C W Roksnoer; Richard van Veghel; René de Vries; Ingrid M Garrelds; Usha M Bhaggoe; Edith C H Friesema; Frank P J Leijten; Marko Poglitsch; Oliver Domenig; Marian C Clahsen-van Groningen; Ewout J Hoorn; A H Jan Danser; Wendy W Batenburg
Journal:  Kidney Int       Date:  2015-04-01       Impact factor: 10.612

3.  Treatment Approaches to Congestion Relief in Acute Decompensated HF: Insights After DOSE-AHF and CARRESS-HF.

Authors:  Simon F Shakar; JoAnn Lindenfeld
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-08

Review 4.  Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.

Authors:  Paul M McKie; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2015-02

5.  How to Improve Adherence to Life-saving Heart Failure Treatments with Potassium Binders.

Authors:  Mitja Lainscak
Journal:  Card Fail Rev       Date:  2017-04

6.  The Mechanism of Action of LCZ696.

Authors:  Juan Tamargo Menendez
Journal:  Card Fail Rev       Date:  2016-05

7.  The burden of heart failure in the general population: a clearer and more concerning picture.

Authors:  Thomas G von Lueder; Stefan Agewall
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 8.  Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide.

Authors:  Tomoko Ichiki; Nina Dzhoyashvili; John C Burnett
Journal:  Int J Cardiol       Date:  2018-06-03       Impact factor: 4.164

Review 9.  Critical Questions about PARADIGM-HF and the Future.

Authors:  Chen-Huan Chen
Journal:  Acta Cardiol Sin       Date:  2016-07       Impact factor: 2.672

10.  Sacubitril/Valsartan.

Authors:  Dennis J Cada; Danial E Baker; James Leonard
Journal:  Hosp Pharm       Date:  2015-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.